Overview
Quinidine is a Class IA antiarrhythmic drug used in the management of both supraventricular and ventricular arrhythmias. It works by blocking fast sodium channels in cardiac tissue, which slows conduction velocity, and by blocking potassium channels, which prolongs action potential duration and the QT interval.
Quinidine also increases the effective refractory period and suppresses abnormal pacemaker activity. Historically, it was used as an antimalarial agent, but its current use is mainly cardiac. Due to its narrow therapeutic index and potential for serious adverse effects, quinidine therapy requires careful clinical and laboratory monitoring.
Symptoms
Symptoms related to quinidine are usually the result of adverse effects or toxic serum levels. Common symptoms include nausea, vomiting, diarrhea, abdominal pain, dizziness, headache, tinnitus, blurred vision, and confusion.
A characteristic dose-related toxicity known as cinchonism presents with tinnitus, headache, visual disturbances, and confusion. Cardiovascular symptoms may include palpitations, hypotension, syncope, and worsening arrhythmias due to QT prolongation and torsades de pointes. In severe toxicity, patients may develop ventricular arrhythmias, marked hypotension, or collapse.
Causes
Adverse effects of quinidine are caused by excessive sodium and potassium channel blockade and accumulation of the drug in the bloodstream. Reduced renal excretion or hepatic metabolism leads to elevated serum levels and increased toxicity.
Drug interactions, especially with medications that inhibit or induce CYP3A4, significantly affect quinidine levels. Electrolyte imbalances such as hypokalemia or hypomagnesemia increase the risk of proarrhythmic effects. Rapid dose escalation or failure to monitor serum concentrations also contributes to toxicity.
Risk Factors
Risk factors for quinidine toxicity include advanced age, renal impairment, hepatic dysfunction, electrolyte disturbances, and pre-existing cardiac conduction abnormalities. Patients with prolonged QT interval, history of torsades de pointes, heart block, myasthenia gravis, or thrombocytopenia are at higher risk.
Concomitant use of other QT-prolonging drugs further increases the likelihood of serious arrhythmias. Slow acetylators and patients with multiple comorbidities are particularly vulnerable.
Prevention
Prevention focuses on appropriate patient selection, dose adjustment, and regular monitoring. Therapeutic drug monitoring helps maintain serum quinidine levels within the therapeutic range and prevents toxicity. Regular ECG monitoring for QT interval prolongation and arrhythmias is essential. Monitoring serum electrolytes, liver function tests, complete blood count, and renal function improves safety. Avoiding interacting drugs, correcting electrolyte imbalances, and early recognition of cinchonism help prevent severe complications and ensure safer long-term quinidine therapy.
